Seltorexant is one of 92 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
386 competitors in Major Depressive Disorder
Daliresp
SAGE-217
Celebrex
Clozaril
Psilocybin
SPD489
Rapastinel
DVS-233
TC-5214
Aticaprant
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details